According to a recent IDC report, GenAI in Healthcare and Life Sciences: Current Trends and Future Potential in Asia/Pacific, over half of healthcare and life sciences organisations in Asia/Pacific are prioritising investments in GenAI projects.
GenAI spending in APAC
The report also revealed that 77% of healthcare and 53% of life sciences organisations in Asia/Pacific focus on proofs of concepts(POCs) and use case identification for GenAI projects.
Further, IDC projects Asia/Pacific to be the fastest-growing region in healthcare and life sciences GenAI spending, accounting for around 15% of the global spending by 2027.
The topmost capabilities CIOs look for in a software provider to develop GenAI solutions are robust data security capability and intuitive AI models However, the top limiting factors for GenAI adoption in healthcare organisations include regulatory risks and higher infrastructure costs.
GenAI benefits in healthcare and life sciences
“GenAI adoption in healthcare and life sciences, though at its nascent stage, is set to have a significant impact on enhancing clinician efficiency, improving workflow productivity, and hyper personalisation of the patient experience. Currently, there is increased priority towards POCs as part of GenAI model deployments; this is set to transition to full-fledged deployments supported by matured clinical data sets, regulatory support, enhanced skill sets, and alignment of GenAI use cases with organisational priorities,” says Manoj Vallikkat, senior research manager, Health Insights, Asia/Pacific.
